Our Research Use Only policy

NoRamp will only onboard RUO peptide suppliers whose customer base is, in fact, researchers — institutional buyers, credentialed labs, contract research organizations, and universities. If your public-facing storefront looks like a consumer brand, ships to individuals at residential addresses, or carries any marketing that implies human use, we will decline. Without exception.

We use Stripe's Prohibited and Restricted Businesses policy as our baseline. If you could not pass Stripe's review, you will not pass ours.

There is a legitimate, well-regulated market for research-grade peptides. Universities, biotech labs, and contract research organizations buy these compounds every day for genuine research purposes, and they deserve a payments partner that does not lump them in with the much larger gray market.

That gray market — consumer-facing storefronts selling the same molecules under a thin “Research Use Only” label while implicitly marketing them for human use — is something we will not touch. Processing for that segment is not just a regulatory risk; it is a real harm to consumers who do not know what they are buying or how to use it safely. We have no interest in being part of it.

Being strict here protects our legitimate merchants. The more carefully we underwrite the category, the more durable a partner we can be for the labs and suppliers doing it right.

The following are immediate declines. This list is not exhaustive and is updated as the regulatory landscape evolves.

• Any consumer-facing marketing — lifestyle photography, influencer partnerships, before-and-after content, social-media ad sets targeting consumers.
• Any dosing instructions, suggested administration guidance, or human-use claims anywhere on the site or in marketing materials.
• Any anti-aging, weight-loss, performance, longevity, hair growth, or other physiological claims tied to the products.
• Order patterns inconsistent with research supply — high-volume small-quantity orders to residential addresses, repeat individual buyers, lack of institutional purchasers.
• Absence of institutional credentialing, purchase order workflows, or buyer verification on the operational side.
• Any history of regulatory action from the FDA, FTC, state attorneys general, or international equivalents.
• Operations that would not pass Stripe's Prohibited and Restricted Businesses policy linked above.

For applicants who pass an initial review, our underwriting process examines:

• Your customer mix — what percentage of revenue comes from institutional buyers, .edu domains, or credentialed labs, and how that mix is verified at point of sale.
• Your buyer verification workflow — how you confirm that a buyer is, in fact, a researcher before accepting an order.
• Your marketing channels — ad placements, content strategy, organic reach, and audience composition.
• Your product catalog and how it is presented — including photography, language, and the absence of human-use indicators.
• Your operational history — chargeback rate, refund patterns, prior processor relationships, and any regulatory correspondence.

Onboarding is not the end of the review. We monitor merchant sites, marketing channels, and order patterns on an ongoing basis. If we see drift toward consumer sales, we will raise it with you directly before taking any account action. If the drift is structural rather than incidental, we will offboard with notice. Our goal is to be a stable, long-term partner to compliant operators — not to surprise anyone.

If your business genuinely serves researchers and you can demonstrate that — institutional buyers, credentialed accounts, clean marketing, no human-use positioning — we would like to talk. The bar is high on purpose, and our existing merchants are the reason.